AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04930185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Description: Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
Study NCT04930185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Description: Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
Study NCT04930185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Description: Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
Study NCT04933162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein and Low Fiber Diet
Description: Protein intake will be increased to be >40% calories from protein, and the fiber intake will remain \<15gm/day.
Study NCT04933162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein and High Fiber Diet
Description: Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
Study NCT04961983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Travel Health Education Model
Description: The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months.
Study NCT05625568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYNT-0126
Description: Liquid for oral administration once daily
Study NCT05625568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid for oral administration once daily
Study NCT05648136 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation
Study NCT05648136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation
Study NCT05663944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy
Description: All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 1st MRI scan
Description: If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
Study NCT06406998 — intervention group
Intervention type: OTHER
Intervention: Pre-existing atherosclerotic cardiovascular disease
Description: Presence of pre-existing atherosclerotic cardiovascular disease
Study NCT06476626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Reflective Function Workshop
Description: 4 session group online intervention focused on psycho-educational knowledge regarding emotional regulation and specifically MRF. group size- up to 15 participants. 2 sessions will be during pregnancy and 2 sessions will taken place 1 and 3 months after birth.
Study NCT06297681 — intervention group
Intervention type: DRUG
Intervention: Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin
Description: The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
Study NCT05663944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1st MRI scan
Description: If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
Study NCT06428721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Study NCT06643416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% eye drops and betamethasone valerate 0.1% cream
Description: Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
Study NCT06643416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Betamethasone valerate 0.1% cream
Description: The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
Study NCT06643416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone valerate 0.1% cream
Description: The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
Study NCT05556850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STABL Virtual Rehabilitation
Description: STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner.
Study NCT05304949 — intervention group
Intervention type: OTHER
Intervention: Lucentis
Description: There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
Study NCT04620590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
Study NCT05359549 — intervention group
Intervention type: DEVICE
Intervention: Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago
Description: All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
Study NCT06463418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekoskeleton (Intervention)
Description: Exoskeleton walking three times per week for 12 weeks.
Study NCT06463418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation (Comparator)
Description: Relaxation three times per week for 12 weeks.
Study NCT04948554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)
Study NCT04948554 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05163821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Manchester Somali Cognitive Assessment Tool
Description: Cognitive screen for dementia
Study NCT05163821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ACE-III Somali Translation
Description: Cognitive screen for dementia
Study NCT06300476 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWK006
Description: Subretinal administration of gene therapy vector JWK006 to one eye.
Study NCT06037694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Free Gingival Graft
Description: Implant site with insufficient dimensions of KM will be covered by a conventional free gingival graft.
Study NCT06037694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'Mesh Free Gingival Graft
Description: Implant site with insufficient dimensions of KM will be covered by a expanded meshed free gingival graft.
Study NCT06260267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiota suspension
Description: Microbiota suspension
Study NCT06260267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiota capsule
Description: Microbiota capsule
Study NCT06260267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: Placebo suspension
Study NCT06260267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule
Study NCT04142320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop rTMS
Description: Delivers patterned magnetic stimulation in closed-loop fashion
Study NCT04142320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: open-loop rTMS
Description: Delivers patterned magnetic stimulation in open-loop fashion
Study NCT04142320 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: Delivers placebo magnetic stimulation
Study NCT06162845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions
Description: Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
Study NCT06162845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based home exercise program for pelvic floor muscle exercise
Description: Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
Study NCT04316442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6129
Description: Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Study NCT05212324 — intervention group
Intervention type: PROCEDURE
Intervention: widening of first web space
Description: widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
Study NCT05809024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
Study NCT05985473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: audiological measurements
Description: audiological measurements
Study NCT05985473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Objective and subjective audiological measurements
Description: Objective and subjective audiological measurements
Study NCT05985473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the denoising methods REFINED
Description: Evaluation of the denoising methods REFINED
Study NCT05432323 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multi-family therapy
Description: 8 sessions of Multi-family therapy of 3 hours each during 24 weeks
Study NCT04038619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT via colonoscopy
Study NCT04038619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Given PO
Study NCT06647732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)
Study NCT06647732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
Study NCT05164731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third does was given 3, 4, 5 or 6 months after two doses
Study NCT06512454 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT05583851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Smartphone app guided and manualized version of acceptance and commitment therapy.
Study NCT05583851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Active Control
Description: Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.
Study NCT05334823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pCAR-19B cells
Description: Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study NCT06017817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Anti-infective photodynamic therapy for plaque-induced oral conditions
Study NCT06017817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene instructions
Description: Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
Study NCT06017817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene instructions
Description: Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
Study NCT06017817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP
Description: non-surgical anti-infective treatment by scaling and root planing
Study NCT06017817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP
Description: non-surgical anti-infective treatment by scaling and root planing
Study NCT06017817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical anti-infective peri-implantitis treatment
Description: surgical anti-infective peri-implantitis treatment
Study NCT06017817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical anti-infective peri-implantitis treatment
Description: surgical anti-infective peri-implantitis treatment
Study NCT06648005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the spinal manipulative therapy combined brace
Description: Besides bracing, the SMTB group was treated with spinal manipulative therapy. If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination.
Study NCT06648005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brace
Description: Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
Study NCT06649474 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
Description: assess the serum HMGB1 concentrations
Study NCT06648174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear.
Study NCT06648174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal nursing care for gestational diabetes
Description: Individual nursing care and consultation for women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum.
Study NCT06648174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood glucose meters (BGM)
Description: Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery, another glucose monitor reports will be given to the participants.